429 related articles for article (PubMed ID: 34647511)
1. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
2. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
3. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
4. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
5. Phytotherapy for treatment of cytokine storm in COVID-19.
Sapra L; Bhardwaj A; Azam Z; Madhry D; Verma B; Rathore S; Srivastava RK
Front Biosci (Landmark Ed); 2021 Apr; 26(5):51-75. PubMed ID: 34027650
[TBL] [Abstract][Full Text] [Related]
6. An Impaired Inflammatory and Innate Immune Response in COVID-19.
Park SH
Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K
Cells; 2021 Jul; 10(7):. PubMed ID: 34359931
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
Mohanty RR; Padhy BM; Das S; Meher BR
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2802-2807. PubMed ID: 33829465
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
12. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
[TBL] [Abstract][Full Text] [Related]
13. A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes.
Cabler SS; French AR; Orvedahl A
Trends Mol Med; 2020 Dec; 26(12):1078-1085. PubMed ID: 33051104
[TBL] [Abstract][Full Text] [Related]
14. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
[TBL] [Abstract][Full Text] [Related]
15. Cytokine storm syndrome in coronavirus disease 2019: A narrative review.
Gao YM; Xu G; Wang B; Liu BC
J Intern Med; 2021 Feb; 289(2):147-161. PubMed ID: 32696489
[TBL] [Abstract][Full Text] [Related]
16. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
[TBL] [Abstract][Full Text] [Related]
18. Covid-19 and development of heart failure: mystery and truth.
Onohuean H; Al-Kuraishy HM; Al-Gareeb AI; Qusti S; Alshammari EM; Batiha GE
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2013-2021. PubMed ID: 34480616
[TBL] [Abstract][Full Text] [Related]
19. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
Gangemi S; Tonacci A
Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
[TBL] [Abstract][Full Text] [Related]
20. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]